Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Overcoming Resistance to Targeted Therapy in Breast Cancer

Award Number: R35CA305347
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/20/2025
PERIOD OF PERFORMANCE END DATE: 07/31/2032

Group Awards By:

View Award Description

Overcoming Resistance to Targeted Therapy in Breast Cancer - PROJECT SUMMARY Therapies directed against lineage and oncoprotein drivers in breast cancer have led to major improvements in clinical outcomes, establishing the significance of these drug targets. In metastatic breast cancer, eventual resistance to these drugs is unfortunately common and represents a major clinical dilemma. We have focused our research efforts on understanding resistance to therapies against the major targets in luminal breast cancer including ER, HER2, PI3K, and CDK4/6. Using a combination of clinic-genomic analyses, advanced breast cancer modeling, and pharmacology, we have identified and characterized common resistance mechanisms such as ESR1 mutations driving endocrine resistance, PTEN loss promoting insensitivity to PI3Ki, and HIPPO pathway alterations and TP53 loss promoting CDK4/6i resistance. Even as these studies have paved the way towards new biomarkers such as ESR1 ctDNA as well as new therapies such as oral SERDs, they have pointed to a deeper challenge of breast cancer plasticity that underlies these acquired genetic alterations. So, despite patients being treated with 2nd generation inhibitors or combinations, we are observing new forms of resistance emerge. However, not all cases of metastatic breast cancer harbor this level of plasticity and there now also exists a growing cohort of patients with long-term disease control that must be understood in comparison. In this next phase of research into therapy resistance, we aim to elucidate the processes underlying plasticity and the resulting therapy resistance centering on three broad questions. First, by what mechanisms do discrete forms of genomic instability such as homologous recombination deficiency or APOBEC3 mutagenesis contribute to therapy resistance. Second, by what effector pathways and mechanisms of cancer cell elimination do we observe durable, long-term response to targeted therapies in subsets of metastatic breast cancer. Third, through which aspects of the antibody-linker-payload construct of Antibody Drug Conjugates do breast cancers develop resistance. The overall goal of this project is to establish the underlying mechanisms of response and resistance to modern targeted therapy in breast cancer and use these insights to develop curative approaches for increasing segments of this common disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,056,000 )
2025	2025	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Treatment Research	000	1	8/19/2025	NEW	$1,056,000
														Subtotal = $1,056,000

Grand Total All Awards = $1,056,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Overcoming Resistance to Targeted Therapy in Breast Cancer

Award Number: R35CA305347

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/20/2025

PERIOD OF PERFORMANCE END DATE: 07/31/2032

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer